 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...1213141516171819202122...3839» |
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. (Pubmed Central) - Jul 1, 2021
CZP was highly effective in RA patients who had low serum TNFα levels at 24 h after the initial administration of CZP. Therefore, we propose that serum TNFα levels at 24 h could serve as a biomarker predicting effectiveness to CZP at week 12 in patients with RA.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Watch Dr. Kathryn Dao discuss pregnancy outcomes with Certolizumab. https://t.co/PjymlCvYY6 (Twitter) - Jun 30, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Jun 28, 2021
P3, N=193, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Therefore, we propose that serum TNFα levels at 24 h could serve as a biomarker predicting effectiveness to CZP at week 12 in patients with RA. Trial completion date: Dec 2023 --> Apr 2024
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Journal: Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. (Pubmed Central) - Jun 26, 2021
This work has highlighted potential differences in treatment response for biologic-naïve patients. When conducting NMAs in any area, heterogeneity in patient characteristics of included trials should be carefully assessed and effect modification related to certain patient characteristics investigated through clinically relevant subgroup analyses.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Journal: Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis. (Pubmed Central) - Jun 26, 2021
The study will use a new modeling approach, which aims at retaining the statistical power. The model may help clinicians individualize treatment for particular patients.
- || Clinical, Journal: Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. (Pubmed Central) - Jun 24, 2021
However, more data are needed to establish effective preventive strategies for HBsAg-negative/HBcAb-positive patients. It seems safe to use cyclosporine and TNF inhibitors in patients with HCV infection, while those undergoing rituximab therapies should be frequently monitored for HCV activity.
- | Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. (Pubmed Central) - Jun 24, 2021
We designed a comprehensive literature search on this topic, by a review of published articles in indexed international journals up until 31st July 2019.Expert opinion: CZP demonstrated positive results in several domains of psoriatic disease, also in patients previously exposed to other TNF-α inhibitors and in patients receiving re-treatment after treatment interruption. The peculiar chemical structure, along with its well-established efficacy and safety, support CZP as the drug of choice in specific subgroups of patients with psoriatic disease, in particular patients with comorbidities and pregnant or breastfeeding female patients.
- ||| Clinical, Review, Journal, Adverse events: Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. (Pubmed Central) - Jun 24, 2021
There is no evidence for a sex difference in endoscopically measured response to biological therapies in IBD patients. However, there is an influence of sex on the occurrence of adverse events.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Trial withdrawal: A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Jun 23, 2021
P3, N=0, Withdrawn, Sponsor: UCB Biopharma SRL
However, there is an influence of sex on the occurrence of adverse events. N=150 --> 0 | Not yet recruiting --> Withdrawn
- || Clinical, Journal: Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. (Pubmed Central) - Jun 22, 2021
N=150 --> 0 | Not yet recruiting --> Withdrawn Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.
- | Retrospective data, Journal: QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study. (Pubmed Central) - Jun 22, 2021
Annual TB screening is important in psoriasis patients under biologic treatment in order to avoid possible latent TB infection reactivation. Indeed, our data showed that even in a low TB prevalence country like Italy, QFT may convert over time in psoriasis patients under biologics in 6.5% of the cases.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Retrospective data, Journal: Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial. (Pubmed Central) - Jun 22, 2021
CZP plus MTX did not reduce JSD-MCP estimated by CAJSA compared with MTX/placebo. Furthermore, clinical remission (DAS28 ≤ 2.6) in patients treated with CZP plus MTX was associated with an increasing JSD, indicating radiographic remission in RA.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. (Pubmed Central) - Jun 22, 2021
Furthermore, clinical remission (DAS28 ≤ 2.6) in patients treated with CZP plus MTX was associated with an increasing JSD, indicating radiographic remission in RA. No abstract available
- || Soliris (eculizumab) / Alexion Pharma, Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Review, Journal: Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. (Pubmed Central) - Jun 16, 2021
Another biologic, eculizumab, the anti-C5a antibody used to treat complement-mediated microangiopathies, is also considered safe due to the unique engineered IgG2/4κ formulation that limits its passage through the placental barrier...Data on breastfeeding are currently available for several biologics. This article reviews the literature available about which drugs are considered safe during pregnancy and lactation, which are not, and on future prospects.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. (Pubmed Central) - Jun 12, 2021
In the first four weeks of treatment, TNFα inhibition showed strong effects on BTMs and Wnt inhibitors, differently from IL-6 blockade. Glucocorticoids induced similar changes; nonetheless, they showed undesired effects on bone formation.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Certolizumab Pegol in the Treatment of Psoriasis: Real-Life Data. (Pubmed Central) - Jun 10, 2021
There were no cases of death from COVID-related disease in our study population or patients hospitalized for COVID-19 related disease. Our results demonstrate that CZP is an effective and safe therapeutic option for patients with moderate-to-severe chrocic plaque psoriasis.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: For certolizumab, a former study found Cmin values > 7.6 mg/L in patients who achieved clinical remission https://t.co/j09DmQpQwA (Twitter) - Jun 9, 2021
- | Review, Journal: Ocular complications of tumour necrosis factor alpha inhibitors. (Pubmed Central) - Jun 9, 2021
However, their ocular side effect profile is incomplete and poorly recognised, with mostly anecdotal cases reported in the literature. In this report we review the literature regarding ocular side effects associated with tumour necrosis factor alpha blockade.
- | Observational data, Retrospective data, Journal: Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. (Pubmed Central) - Jun 9, 2021
However, hepatotoxicity and nephrotoxicity are among known adverse effects of these agents. Based on the existing literature data, routine monitoring of patients in terms of potential hepatic and renal toxicity before and after treatment remains a valid recommendation in clinical practice.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Journal: A bibliometric analysis of global research output on network meta-analysis. (Pubmed Central) - Jun 8, 2021
Compared with developing countries, developed countries have contributed more to these publications and have closer cooperation, indicating that cooperation between developed and developing countries should be further strengthened. The treatment of diabetes, cardiovascular diseases, and immune rheumatism are the main hot topics.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Disease Activity and Inflammation Following Withdrawal of Certolizumab Pegol Treatment in Axial Spondyloarthritis Patients Who Did Not Experience Flares during the C-OPTIMISE Study (Room 1) - Jun 7, 2021 - Abstract #EULAR2021EULAR_4752;
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Pharmacovigilance Pregnancy Data in a Large Population of Patients with Chronic Inflammatory Disease Exposed to Certolizumab Pegol: Pregnancy Outcomes and Confounders (Room 8) - Jun 7, 2021 - Abstract #EULAR2021EULAR_4521;
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
P3 data, Retrospective data, Journal: Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies. (Pubmed Central) - Jun 4, 2021
P3
No new safety signals were identified compared to previously reported data. Risk did not increase with longer or higher CZP exposure.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, P3 data, Journal: Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2). (Pubmed Central) - Jun 4, 2021
P3
Risk did not increase with longer or higher CZP exposure. Both CZP 200 mg and 400 mg Q2W demonstrated sustained, durable efficacy, with numerically higher responses for some outcomes with 400 mg Q2W.
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow (Twitter) - Jun 4, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Long-term efficacy of certolizumab pegol for psoriasis. (Pubmed Central) - Jun 3, 2021
Both CZP 200 mg and 400 mg Q2W demonstrated sustained, durable efficacy, with numerically higher responses for some outcomes with 400 mg Q2W. No abstract available
- || Retrospective data, Review, Journal: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) - Jun 1, 2021
Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
- |||| FDA event: FDA approval history in #IBD 1998 Infliximab CD 2005 Infliximab UC 2007 Adalimumab CD 2008 Natalizumab CD 2008 Certolizumab CD 2012 Adalimumab UC 2013 Golimumab UC 2014 Vedolizumab UC and CD 2016 Ustekinumab CD 2018 Tofacitinib UC 2019 Ustekinumab UC 2021 𝙤𝙯𝙖𝙣𝙞𝙢𝙤𝙙 UC (Twitter) - May 28, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study. (Pubmed Central) - May 28, 2021
fMRI was carried out at screening as well as after 12 and 24 weeks of receiving CZP or placebo. We hypothesize that high-level central nervous representation of pain in patients with rheumatoid arthritis predicts response to the TNFi CZP which we further investigate in the PreCePRA trial.
- | Journal: Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. (Pubmed Central) - May 22, 2021
Lymphocyte‑targeting agents include rituximab and belimumab, which act against B cells by different mechanisms, and abatacept, which is a T cell costimulation modulator...Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, and upadacitinib) and phosphodiesterase 4 inhibitors (apremilast) form this group...During pregnancy limited data exits, but anti-TNFα, rituximab, and anakinra seem to be safe. Biologic agents are expensive, but biosimilars have raised as a more cost-effective option and an opportunity to treat a greater number of patients.
- | Retrospective data, Journal: Model-Based Meta-analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development. (Pubmed Central) - May 22, 2021
Clinical trial simulations using the present MBMA indicated that abatacept, certolizumab, etanercept, tocilizumab, and tofacitinib would be expected to have a greater than 70% probability of showing a statistically significant difference versus control at Week 6 with a sample size of ~30 patients/arm. In future RA clinical trials, an interim analysis conducted as early as 6 weeks after treatment initiation, with relatively small sample sizes, should be sufficient to detect the ΔDAS28 treatment effect versus placebo.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Review: Editorial on great study from mayo clinic on certolizumab drug concentrations by @GuiRamosMD @EdwardLoftus2. https://t.co/QFAwkOppS3 Also review some previous data by Niels Vande Casteele on models from rct data and music trial by @JeanFredericCo1 (Twitter) - May 21, 2021
- [VIRTUAL] CERTOLIZUMAB PEGOL RELOADING SUCCESSFULLY CONTROLS INFLAMMATORY ARTHRITIS FLARES DURING PREGNANCY – A CASE REPORT () - May 21, 2021 - Abstract #EULAR2021EULAR_3872;
Reloading CZP to control increased IA disease activity during pregnancy may be a viable treatment option. To our knowledge, this is the first report of dose optimization in IA and in pregnancy in a patient treated with CZP.
- [VIRTUAL] ONE YEAR FOLLOW-UP SAFETY AND EFFICACY RESULTS OF VACCINATION PROTOCOL FROM A RHEUMATOLOGY CLINIC () - May 21, 2021 - Abstract #EULAR2021EULAR_3788;
In our cohort, the vaccination protocol proved to be a good tool to improve the vaccination rate of rheumatological patients, despite this, the vaccination of Hepatitis B and specially of influenza, continues to have a lower prevalence to general population.The vaccines were effective since none of the preventable infections occurred during follow up, despite the use of an immunosuppressant. Vaccination showed a good safety profile, without reported serious adverse effects or worsening of the underlying disease.
- [VIRTUAL] SEVERE BREAST ULCERATION IN BEHÇET’S DISEASE TREATED WITH CYCLOPHOSPHAMIDE: A CASE REPORT () - May 21, 2021 - Abstract #EULAR2021EULAR_3729;
Similar presentations in Behcet’s disease have been recognised 2 , although much less commonly. Our case demonstrates that severe breast ulceration can be a clinical manifestation of this condition and can be refractory to usual therapies.
- [VIRTUAL] SUCCESSFUL TEATMENT OF ANKYLOSING SPONDILITIS ASSOCIATED AA AMYLOIDOSIS WITH SECUKINUMAB: A CASE SERIES WITH THREE PATIENTS () - May 21, 2021 - Abstract #EULAR2021EULAR_3726;
AA amyloidosis is a rare complication of SpA, and SEC treatment was found to be safe and effective in our three patients with AS-AA. Although anti-TNF agents have previously used successfully in treatment of AS-AA, SEC may be a new option especially in patients who are resistant or intolerant to anti-TNFs.
- [VIRTUAL] SHORT-TERM OUTCOMES OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES WHO ARE TREATED BY BIOLOGICAL AND TARGETED SYNTHETIC DMARDS: OBSERVATIONAL SINGLE-CENTER STUDY () - May 21, 2021 - Abstract #EULAR2021EULAR_3493;
In this observational study, we found no association between biologic and targeted therapy for rheumatic diseases and severe course of new coronavirus infection, as well as with the need for hospitalization for COVID-19. The outcome of COVID-19 was favorable in all patients receiving treatment with biological and targeted synthetic drugs for rheumatic diseases.
- [VIRTUAL] THE COURSE OF COVID-19 INFECTION IN PATIENTS WITH ARTHRITIS RECEIVING TARGETED DMARDS () - May 21, 2021 - Abstract #EULAR2021EULAR_3490;
Used of tsDMARDs doesn’t reliably increase the risk of COVID-19 severity. There is reliable correlation between age and COVID-19 severity.
- Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] INCIDENCE AND SEVERITY OF COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS IN ARGENTINA: EXPERIENCE IN A COUNTRY WITH STRICT ISOLATION () - May 21, 2021 - Abstract #EULAR2021EULAR_3477;
Regarding the treatments: 4 (28.6%) were in treatment with anti TNF (3 with Adalimumab, 1 with certolizumab pegol), 4 (28.6%) with Anti IL17 (3 with Secukinumab, 1 with Ixekizumab), 8 (57%) with methotrexate and 2 (14%) with Leflunomide. An incidence of 4.4% of COVID-19 was found in this population with SpA and most of the patiend had mild symptoms and no deaths were reported.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] INFECTION PROFILE OF IMMUNE-MODULATORY DRUGS USED IN AUTOIMMUNE DISEASES: ANALYSIS OF SUMMARY OF PRODUCT CHARACTERISTIC DATA () - May 21, 2021 - Abstract #EULAR2021EULAR_3421;
The findings can be used to visualise differences and aid treatment decisions. However, some of the patterns we have shown lack face-validity to clinicians familiar with real-world safety data.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] FOLLOW-UP IN A MULTIDISCIPLINARY UNIT IMPROVES PREGNANCY OUTCOME IN INFLAMMATORY ARTHROPATIES ON BIOLOGICAL THERAPY () - May 21, 2021 - Abstract #EULAR2021EULAR_3034;
Fewer abortions were registered during follow-up in the multidisciplinary unit. Appropriate disease control was maintained during pregnancy, also previously and afterwards.
- [VIRTUAL] EARLY REAL-WORLD EXPERIENCE OF TOFACITINIB FOR PSORIATIC ARTHRITIS: DATA FROM A UNITED STATES HEALTHCARE CLAIMS DATABASE () - May 21, 2021 - Abstract #EULAR2021EULAR_2466;
High levels of persistence and adherence to tofacitinib were observed 6 months after treatment initiation. Findings were similar when pts with PsA who also had a diagnosis of RA were excluded.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] DISEASE DURATION AND HLA-B27 POSITIVITY ALTER LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS () - May 21, 2021 - Abstract #EULAR2021EULAR_2462;
Moreover, bDMARD naive patients have higher retention rate. Drug survival of CZP in patients with PsA Baseline characteristics of PsA patients who continue and discontinue CZP
- [VIRTUAL] PRESCRIPTION PATTERNS OF THE SECOND BIOLOGIC DMARD IN PSORIATIC ARTHRITIS THROUGH THE LAST DECADE: HURBIO-PsA REAL LIFE EXPERIENCE () - May 21, 2021 - Abstract #EULAR2021EULAR_2437;
Non-Anti-TNF bDMARDs, especially secukinumab, becoming more frequently used as a second-line biologic agent in PsA in recent years. These bDMARD prescription trend is appropriate to EULAR PsA recommendations.
- [VIRTUAL] EFFICACY OF TNF INHIBITORS IN MONOTHERAPY VERSUS COMBINATION THERAPY WITHcsDMARDs IN PORTUGUESE PATIENTS WITH PSORIATIC ARTHRITIS: A REAL-WORLD STUDY () - May 21, 2021 - Abstract #EULAR2021EULAR_2435;
In patients without spondyloarthritis, iTNF monotherapy did not differ significantly in terms of response to treatment and disease activity measures, nor does monotherapy predict bDMARD failure and treatment response. These results suggest that iTNF monotherapy is possible in PsA without compromising treatment response.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] TROUGH LEVELS OF TNF-Α INHIBITORS AND THEIR IMMUNOGENICITY IN THE TREATMENT OF RHEUMATIC DISEASES AND INFLAMMATORY BOWEL DISEASES () - May 21, 2021 - Abstract #EULAR2021EULAR_2161;
For each group, the factors associated with a low trough level of TNFi were identified. There were no significant differences in the frequency of ADAb formation between nosologies.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN AXIAL SPONDYLOARTHRITIS IS HIGHER: DATA FROM TURKBIO () - May 21, 2021 - Abstract #EULAR2021EULAR_2157;
Higher baseline disease activity and functional limitation predict discontinuation of CZP. Adding NSAIDs and csDMARDs to the treatment of the patient with poor prognosis cannot increase retention rates.
- [VIRTUAL] IN PREVIOUSLY BIOLOGIC-NAÏVE RHEUMATIC PATIENTS WITH DRUG INDUCED LUPUS SECONDARY TO A FIRST ANTI-TNF THERAPY, IS IT SAFE TO SWITCH TO A SECOND ANTI-TNF-α AGENT? () - May 21, 2021 - Abstract #EULAR2021EULAR_2156;
It seems that exist a low rate of DILE recurrence with an alternative anti-TNF-α agent. Thus, this condition seems to be drug specific rather than class related.
- [VIRTUAL] COMPARATIVE EFFECTIVENESS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN REAL CLINICAL PRACTICE ACCORDING TO THE MOSCOW UNIFIED ARTHRITIS REGISTER (MUAR) () - May 21, 2021 - Abstract #EULAR2021EULAR_2154;
The effect of golimumab and sekukinumab which have been recently introduced into clinical practice doesn’t differ significantly from the effect of TNF inhibitors which has been used for a long time. Achieved values of the indices of activity and functional ability against the background of treatment with bDMARDs.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] TREATMENT OF ANKYLOSING SPONDYLITIS (AS) DURING PREGNANCY () - May 21, 2021 - Abstract #EULAR2021EULAR_2151;
Withdrawal of TNF inhibitors on the eve of pregnancy is a predictor of high AS activity. It is necessary to increase the knowledge of rheumatologists and patients about the therapeutic possibilities during pregnancy to avoid unjustified drug withdrawal.